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Cellular responses to DNA-damaging agents involve the activation of various DNA damage signaling and
transduction pathways. Using quantitative and high-resolution tandem mass spectrometry, we determined
global changes in protein level and phosphorylation site profiles following treatment of SILAC (stable isotope
labeling by amino acids in cell culture)-labeled murine embryonic stem cells with the anticancer drug cisplatin.
Network and pathway analyses indicated that processes related to the DNA damage response and cytoskeleton
organization were significantly affected. Although the ATM (ataxia telangiectasia mutated) and ATR (ATM
and Rad3-related) consensus sequence (S/T-Q motif) was significantly overrepresented among hyperphosphor-
ylated peptides, about half of the >2-fold-upregulated phosphorylation sites based on the consensus sequence
were not direct substrates of ATM and ATR. Eleven protein kinases mainly belonging to the mitogen-activated
protein kinase (MAPK) family were identified as being regulated in their kinase domain activation loop. The
biological importance of three of these kinases (cyclin-dependent kinase 7 [CDK7], Plk1, and KPCD1) in the
protection against cisplatin-induced cytotoxicity was demonstrated by small interfering RNA (siRNA)-medi-
ated knockdown. Our results indicate that the cellular response to cisplatin involves a variety of kinases and
phosphatases not only acting in the nucleus but also regulating cytoplasmic targets, resulting in extensive
cytoskeletal rearrangements. Integration of transcriptomic and proteomic data revealed a poor correlation
between changes in the relative levels of transcripts and their corresponding proteins, but a large overlap in
affected pathways at the levels of mRNA, protein, and phosphoprotein. This study provides an integrated view
of pathways activated by genotoxic stress and deciphers kinases that play a pivotal role in regulating cellular
processes other than the DNA damage response.
Cancer chemotherapy drugs are designed to selectively
kill cells that divide rapidly, which is a main feature of most
cancer cells. Cisplatin [cis-diamminedichloroplatinum(II);
CDDP] is among the most widely employed drugs in che-
motherapy administered as a curative treatment for several
forms of cancer, including ovarian, cervical, head and neck,
esophageal, non-small-cell lung, and, especially, testicular
cancer (23, 26, 32). Cisplatin binds to DNA and forms a
spectrum of intra- and interstrand DNA cross-links as well
as mono adducts. These DNA adducts are thought to me-
diate their cytotoxic effects by interfering with transcription
and replication, ultimately leading to the induction of apop-
tosis (62). Cisplatin adducts distort the DNA duplex, result-
ing in the exposure of the DNA minor groove, to which
several classes of proteins can bind, including high-mobility
group (HMG) proteins and transcription factors that con-
tribute to cisplatin-induced toxicity (70).
Repair of cisplatin-DNA adducts involves proteins from
multiple DNA repair pathways: i.e., nucleotide excision repair
(NER), homologous recombination, postreplication repair,
and mismatch repair (MMR) (11, 70). NER is the major path-
way responsible for the removal of cisplatin-DNA adducts in
vitro and in vivo (15, 69), and hence, the marked sensitivity of
testicular cancer to cisplatin has been correlated with low lev-
els of NER proteins, i.e., XPA and ERCC1-XPF (74). DNA
damage caused by cisplatin activates several signal transduc-
tion pathways, including mitogen-activated protein kinase
(MAPK), AKT, c-ABL, and ATM (ataxia telangiectasia mu-
tated)/ATR (ATM and Rad3-related)/DNA-protein kinase
(PK)-dependent pathways regulating a variety of processes,
such as drug uptake, DNA damage signaling, cell cycle arrest,
DNA repair, and cell death (70).
Treatment of patients with cisplatin is compromised by the
substantial risk of severe toxicity—i.e., anemia, nausea, and
neurotoxicity (31). Tumors frequently become resistant to the
drug (4, 37), and multiple resistance mechanisms have been
identified, including increased cellular efflux or decreased cel-
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lular import of cisplatin (16, 53). Cisplatin resistance can also
occur through enhanced DNA damage repair or increased
tolerance to DNA damage (4).
Improvement of cancer therapy mediated by chemothera-
peutic drug agents such as cisplatin requires better understand-
ing of the cellular pathways underlying toxicity and drug resis-
tance. Indeed, most of the recent advances in cancer treatment
are based on drastic improvements in conceptual understand-
ing of cellular networks. Cellular responses to DNA damage
such as cisplatin-induced intra- and interstrand DNA cross-
links are controlled by a global signaling network called the
DNA damage response (DDR) (17) and mediated by post-
translational protein modifications (6). One of the most fre-
quent modifications is the reversible and dynamic phosphory-
lation of proteins at specific serine, threonine, and tyrosine
residues that control the activity of the majority of cellular
processes. It has been estimated that almost 70% of all pro-
teins in mammalian cells are phosphorylated at some point
during their expression (42). Key signaling molecules in DDR
are the protein kinases ATM (ataxia telangiectasia mutated)
and ATR (ATM and Rad3-related) (1). Matsuoka and co-
workers recently identified over 900 phosphorylation sites in
about 700 proteins by phosphoproteome analysis of proteins
targeted by the ATM and ATR kinases after exposure to ion-
izing radiation (30); however, knowledge of the genomewide
protein phosphorylation response to genotoxic insults is still
limited. This study aimed to identify the molecular processes
and cellular pathways that are affected after treatment with
cisplatin, one of the most commonly used chemotherapeutic
drugs. To achieve these goals, we examined the cisplatin-in-
duced stress responses, changes in protein level, and global
phosphorylation site profiles by quantitative phosphoproteom-
ics. Besides activation of the DDR kinases ATM and ATR, we
identified 11 other protein kinases with altered activities in
response to cisplatin. We applied small interfering RNA
(siRNA)-mediated knockdown to demonstrate that 3 kinases
have important protective roles in the cellular response to
cisplatin-induced toxicity. Our data set identified the cytoskel-
eton as a novel target of the cisplatin-induced stress response.
In addition, integration of transcriptome, proteome, and phos-
phoproteome data disclosed a strong correlation in the af-
fected pathways at the levels of transcription and protein phos-
phorylation.
MATERIALS AND METHODS
Cell culture and cisplatin treatment. Cell culture and cisplatin treatment of
wild-type mouse embryonic stem (mES) cells (B4418 and HM1 derived from the
C57/Bl6 and OLA/129 mouse genetic backgrounds, respectively) were essentially
performed as previously described (24). Subconfluent cultures of mES cells were
exposed to cisplatin (5 M) added directly to the culture medium. Cell cultures
were incubated for different periods after cisplatin administration (0.5, 2, 4, and
8 h). The Thermo Scientific Pierce mouse embryonic stem cell kit, containing
media and reagents specifically designed for analysis of protein by mass spec-
trometry (Thermo Scientific), was used for SILAC (stable isotope labeling by
amino acids in cell culture) experiments.
Phosphopeptide enrichment. Isolation and purification of phosphopeptides
were performed according to already published procedures (68), with some
modifications. Briefly, cells were lysed for 30 min in lysis buffer (8 M urea, 50 mM
Tris [pH 8.1], 75 mM NaCl, 1 mM MgCl2, 500 U benzonase and phosphatase
inhibitors). Samples were centrifuged for 15 min at 13,000 rpm, and the protein
concentration was established by Qubit protein assay (Invitrogen). Ten milli-
grams of proteins was first reduced with 2.5 mM dithiothreitol (DTT) for 25 min
at 60°C and subsequently alkylated by incubation with 7 mM iodoacetamide for
15 min at room temperature, protected from light. The alkylation reaction was
quenched by incubation with 2.5 mM DTT for 15 min at room temperature.
Protein solution was diluted 8-fold with 25 mM Tris (pH 8.1)–1 mM CaCl2 and
incubated for 15 h at 37°C with 100 g trypsin (Promega). On the following day,
the digestion reaction was stopped by addition of trifluoroacetic acid (TFA) to a
0.4% final concentration, and the precipitate was removed by centrifugation for
5 min at 3,200 rpm. The supernatant was loaded on a Sep-Pak Vac 1-ml C18
cartridge (Waters), desalted by washing with 0.1% acetic acid, and eluted with
0.1% acetic acid–30% acetonitrile. Eluted peptides were lyophilized and frac-
tionated at 1 ml/min on a 9.4- by 200-mm 5-m-particle polysulfoethyl A strong
cation exchange (SCX) column (PolyLC) using a 70-min gradient from 0 to 75
mM KCl, with 350 mM KCl for 38 min in 5 mM KH2PO4 (pH 2.65), and 30%
acetonitrile. Eighteen fractions with 6 ml eluate were collected, desalted on a
Sep-Pak Vac 1-ml C18 cartridge, and lyophilized as described above before. In
the desalting step, the last eight fractions were reduced to four fractions by
loading two fractions on one cartridge, giving a total of 14 fractions. After
lyophilization, peptides were dissolved in solution A (300 mg/ml lactic acid, 80%
acetonitrile, 0.1% TFA) and loaded on a titanium tip column (TopTip 1100 l;
Glycen Corporation) prewashed with elution solution (15 mM NH4OH,
pH10.5), equilibration solution (0.1% TFA), and solution A. After sample
loading, the tip column was washed with solution A and B (80% acetonitrile
[vol/vol], 0.1% TFA [vol/vol]). After washing, phosphopeptides were eluted with
elution buffer and collected in an equal volume of 2% TFA. For desalting,
phosphopeptides were loaded on a Stage Tip C18 column (Proxeon) prewashed
with methanol, solution B, and 0.1% TFA. The phosphopeptide solution was
loaded on a Stage Tip column, washed with 0.1% TFA, and eluted with solution
B. Liquid was removed by lyophilization and stored at 80°C until mass spec-
trometry (MS) analysis.
Mass spectrometric analysis. (i) LC-MS/MS. The dried phosphopeptide mix-
tures were acidified with 5% acetonitrile in 0.3% trifluoroacetic acid (TFA) to an
end volume of 10 l, transferred to a 96-well plate, and analyzed by online
nanoflow liquid chromatography-tandem mass spectrometry (nano-LC-MS/MS)
as described previously (41) with a few modifications. Briefly, all nano-LC-MS/
MS-experiments were performed on an EASY-nLC system (Proxeon Biosystems,
Odense, Denmark) connected to the LTQ-Orbitrap Velos (Thermo Electron,
Bremen, Germany) through a nanoelectrospray ion source.
Five microliters of each phosphopeptide fraction was autosampled onto and
directly separated in a 15-cm analytical column (75-m inner diameter) packed
in-house with 3-m C18 beads (Reprosil-AQ Pur, Dr. Maisch) with a 90-min
gradient from 5% to 30% acetonitrile in 0.5% acetic acid at a flow rate of 250
nl/min. The effluent from the high-performance liquid chromatography (HPLC)
was directly electrosprayed into the mass spectrometer by a platinum-based
liquid junction.
The LTQ-Orbitrap Velos instrument was operated in the data-dependent
mode to automatically switch between full-scan MS and MS/MS acquisition.
Instrument control was through Tune 2.6.0, and Xcalibur 2.1 Survey full-scan MS
spectra (from m/z 300 to 2,000) were analyzed in the Orbitrap detector with
resolution of 30,000 at m/z 400 (after accumulation to a “target value” of 1e6 in
the linear ion trap). The 10 most intense peptide ions with charge states of 2
were sequentially isolated to a target value of 5e4 and fragmented in an octopole
collision cell by higher-energy collisional dissociation (HCD) with a normalized
collision energy setting of 40%. The resulting fragments were detected in the
Orbitrap system with resolution of 7,500. The ion selection threshold was 5,000
counts, and the maximum allowed ion accumulation times were 500 ms for full
scans and 250 ms for HCD.
Standard mass spectrometric conditions for all experiments were as follows:
spray voltage, 2.2 kV; no sheath and auxiliary gas flow; heated capillary temper-
ature, 275°C; predictive automatic gain control (pAGC) enabled, and an S-lens
RF level of 65%. For all full-scan measurements with the Orbitrap detector, a
lock mass ion from ambient air (m/z 445.120024) was used as an internal cali-
brant as described previously (39). A setting was also chosen where the addi-
tional single injection method (SIM) injection of the lock mass is deactivated, in
order to save time.
(ii) Raw MS data analysis: peptide identification and quantitation by
MASCOT andMaxQuant. Raw Orbitrap full-scan MS and ion trap MSA spectra were
processed by MaxQuant as described previously (7, 8). In brief, all identified
SILAC doublets were quantified, accurate precursor masses were determined
based on intensity-weighing precursor masses over the entire LC elution profiles,
and MS/MS spectra were merged into peak-list files (*.msm). Peptides and
proteins were identified by Mascot (Matrix Science, London, United Kingdom)
via automated database matching of all tandem mass spectra against an in-house
curated concatenated target/decoy database; a forward and reversed version of
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the mouse International Protein Index (IPI) sequence database (version 3.37;
102,934 forward and reversed protein sequences from EBI [http://www.ebi.ac.uk
/IPI/]) supplemented with common contaminants such as human keratins, bovine
serum proteins, and porcine trypsin. Tandem mass spectra were initially matched
with a mass tolerance of 7 ppm on precursor masses and 0.02 Da for HCD
fragment ions. Scoring was performed in MaxQuant as described previously. We
required strict trypsin enzyme specificity and allowed for up to two missed
cleavage sites. Cysteine carbamidomethylation (Cys, 57.021464 Da) was
searched as a fixed modification, whereas N-acetylation of proteins (N-terminal,
42.010565 Da), N-pyroglutamine (17.026549 Da), oxidized methionine
(15.994915 Da), and phosphorylation of serine, threonine, and tyrosine (Ser/
Thr/
Tyr, 79.966331 Da) were searched as variable modifications.
Peptide filtering and phosphorylation site localization. The resulting Mascot
result files (*.dat) were loaded into the MaxQuant software suite for further
processing. In MaxQuant, we fixed the estimated false discovery rate (FDR) of
all peptide and protein identifications at 1%, by automatically filtering on pep-
tide length, mass error precision estimates, and the Mascot score of all forward
and reversed peptide identifications. Finally, to pinpoint the actual phosphory-
lated amino acid residue(s) within all identified phosphopeptide sequences in an
unbiased manner, MaxQuant calculated the localization probabilities of all pu-
tative serine, threonine, and tyrosine phosphorylation sites, using the PTM score
algorithm as described previously (38).
Phosphorylation site sequence motif logo plots. Only peptides with localiza-
tion probabilities of 0.75 were included in the downstream bioinformatic anal-
ysis (see Table S1 in the supplemental material). To identify enriched sequence
motifs in the phosphorylation site data set, we made use of the already published
kinase motifs (www.phosida.com) and an algorithm that extracts overrepre-
sented motifs in a more unbiased manner (58). The algorithm was implemented
in R (a programming language and software environment for statistical comput-
ing and graphics), using a Fisher’s exact test to iteratively test for position-
specific overrepresentation of amino acid groups between two lists of prealigned
sequences. The perl-package WebLogo was used internally in the algorithm to
visualize the enriched sequence motifs as logo plots. Grouping of amino acids
was done on the basis of related chemical properties (acidic, basic, aromatic,
aliphatic, hydrophilic, amide, polar, and cyclic), and alignment was done with a
sequence window of 6 amino acids surrounding the central phosphorylated
serine, threonine, or tyrosine residue. The iterative nature of the algorithm
means it is successively reapplied on the result from an analysis—i.e., on both the
subset of the lists which contains the most significantly overrepresented amino
acid group and the subset that does not contain this amino acid group. All
cisplatin-regulated phosphorylation site sequences were compared to all un-
changing sites and vice versa. We considered a motif significant if it fulfilled our
conservative cutoff of P  0.001 on the Bonferroni adjusted P values.
Network and pathway analyses. Network and pathway analyses were per-
formed using MetaCore software (http://www.genego.com/metacore.php). Pro-
teins containing upregulated phosphorylation sites (1.5-fold and 2-fold) and
downregulated phosphorylation sites (1.5-fold and 2-fold) were investigated.
In most cases, high-throughput experiments result in lists of genes or proteins of
interest. The data sets usually contain anywhere between a few dozen and few
thousand genes/proteins. In MetaCore, the significance is evaluated based on the
size of the intersection between the user’s data set and set of genes/proteins
corresponding to a network module/pathway in question, or rather the proba-
bility to randomly obtain an intersection of a certain size between the user’s set
and a network/pathway follows a hypergeometric distribution. The significance of
the networks/pathways is evaluated for whether the algorithm has succeeded in
creating modules that have a higher-than-random saturation with the genes of
interest.
Networks are drawn from scratch by GeneGo annotators and manually cu-
rated and edited. There are about 110 cellular and molecular processes whose
contents have been defined and annotated by GeneGo. Canonical pathway maps
represent a set of about 650 signaling and metabolic maps covering human
biology (signaling and metabolism) in a comprehensive way.
Western blot analysis. Total cell extracts were obtained by direct lysis of the
cells in Laemmli-SDS-sample buffer. Western blot analysis was performed as
described previously (13), and protein bands were analyzed and visualized with
the Odyssey infrared imaging system (LI-COR) using secondary antibodies la-
beled with visible fluorophores. The antibodies employed were mouse anti--
H2AX (Millipore), rabbit anti-H2B (Santa-Cruz), mouse anti-p53 (Santa Cruz
Biotechnology DO-1), rabbit anti-cyclin-dependent kinase 7 (anti-CDK7; Cell
Signaling), rabbit anti-PLK1 (Cell Signaling), rabbit anti-KPCD1 (Cell Signal-
ing), rabbit anticentrin (Cell Signaling), rabbit anti-E-cadherin (Cell Signaling),
and rabbit anti-mark2 (Cell Signaling).
Flow cytometry analysis. For cell cycle analysis, samples were either treated
with 5 M cisplatin for 0.5, 2, 4, or 8 h or mock treated, after which 5-ethynyl-
2	-deoxyuridine (EdU) label was added to a final concentration of 20 M. Cells
were collected 45 min after addition of EdU label and stained for EdU and DNA
using the Click-iT EdU flow cytometry assay kit (Invitrogen) according to the
manufacturer’s protocol.
To determine the mitotic index, samples were either treated with 5 M
cisplatin for 0.5, 2, 4, or 8 h, treated with 100 ng/ml nocodazole for 4 h, or mock
treated. Cells were collected and 106 cells were fixed with 70% ethanol. Cells
were washed with phosphate-buffered saline (PBS) and incubated with rabbit
anti-phospho-Ser10 histone H3 antibody (Millipore). After washing, samples
were incubated with goat anti-rabbit antibody–Alexa Fluor 488 (Invitrogen).
After washing, cells were treated with RNase A (200 g/ml) and stained with
propidium iodide (Bio-Rad). Cells were analyzed using a BD LSR II flow
cytometer (BD Biosciences) and FACSDiva 5.0 software. Results were analyzed
with WinMDI 2.8 software.
Immunofluorescence staining. Cells were fixed in 4% formaldehyde in CSK
buffer, consisting of 100 mM NaCl, 300 mM sucrose, 10 mM PIPES [piperazine-
N,N	-bis(2-ethanesulfonic acid); pH 6.8],and 3 mM MgCl2, and permeabilized by
treatment with 0.5% Triton X-100 in PBS for 10 min. Actin was visualized by
DY554-phalloidin (Sigma-Aldrich), and cells were counterstained with DAPI.
Images were captured with a Zeiss Axioplan2 microscope equipped with a Zeiss
Axiocam MRm camera using either a Plan-NEOFLUAR 40
/1.30 or 63
/1.25
objective.
siRNA transfection. HM1 mES cells were transfected with a 50 nM final
concentration of siRNA (Dharmacon), targeting for CHK2, CDK7, MAPK2,
M3K2, MK14, MARK1, PDPK1, PLK1, KPC1, KPCD1, and SG269, as well as
siRNA coding for green fluorescent protein (siGFP; control 1) and siRNA
coding for LAMIN A/C (siLAMIN A/C; control 2), which were used as negative
controls. Transfection was performed using Dharmafect 1 (Dharmacon) accord-
ing to the manufacturer’s instructions. A total of 103 HM1 mES cells were
transfected for 16 h in Clear 96-well plates (Greiner), and the medium was
refreshed every 24 h for 48 h.
Cell viability assay. At 64 h post-siRNA transfection, HM1 mES cells were
treated with either vehicle or 10 M cisplatin (Ebewe Pharma) for 24 h. ATP
Lite (Perkin Elmer) was then used for the assessment of cell viability according
to the manufacturer’s instructions. As an additional confirmation that cisplatin
was inducing apoptosis, the pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-DL-
Asp(OMe)-fluoromethylketone (zVAD-fmk) (Bachem, Bubendorf, Switzerland)
was used to inhibit caspases and block cisplatin-induced apoptosis (see Fig. S4A
in the supplemental material).
Gene expression analysis. The gene expression levels of Cdh1, p53, centrin2,
and mark2 were quantified after exposure to 5 M cisplatin for 4 h using
quantitative reverse transcriptase-PCR (qRT-PCR). The qRT-PCR was per-
formed using the Applied 7900ht real-time PCR detection system (Applied
Biosystems). In three independent experiments, the RNA was isolated from mES
cells and purified using an RNeasy kit (Qiagen). qRT-PCR was performed using
the FastStart Universal SYBR green master (Rox) (Roche) according to the
manufacturer’s instructions.
The following primers were used: Cdh1 forward (ATCCTCGCCCTGCTG
ATT) and reverse (ACCACCGTTCTCCTCCGTA), p53 forward (ATGCCCA
TGCTACAGAGGAG) and reverse (AGACTGGCCCTTCTTGGTCT), cen-
trin2 forward (TGAGACTGGGAAAATATCATTCAA) and reverse (CACCA
TCTCCATCTCGATCA), and mark2 forward (GAAAGGGACACGGAG
CAG) and reverse (CCGCAGCATGTTGGACTT).
mRNA expression values were normalized to the housekeeping gene coding
for hypoxanthine guanine phosphoribosyltransferase (HPRT).
RESULTS
Cisplatin-induced stress responses. Murine embryonic stem
(mES) cells were selected as the cellular model for this study
since they have the unique combination of a virtually infinite
life span with uncompromised DDR. mES cells manage to
maintain their genomic integrity through robust defense mech-
anisms against DNA damage, including effective DNA repair
and a hypersensitive apoptotic response (61). These character-
istics make mES cells suitable to study the molecular events
that underlie the cellular responses related to cisplatin-induced
toxicity. To assess the kinetics of the cisplatin-induced stress
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response, we examined cell cycle progression, mitotic index,
and DNA strand breaks (by staining for -H2AX) in cisplatin-
exposed mES cells over time. Cell cycle analysis following
DNA synthesis labeling by EdU showed that, in the absence of
cisplatin, about 65% of the ES cells were in S phase (G1,
15%; and G2/M, 20%; see Fig. S1A in the supplemental
material). After addition of cisplatin, we observed a time-
dependent inhibition of DNA synthesis: the incorporation of
EdU was evident at 30 min, decreased after 2 h, and was
completely absent at 4 and 8 h (Fig. 1A). Inhibition of DNA
replication and transcription has been widely considered to be
a key to the mechanism of cisplatin cytotoxicity (62). No sig-
nificant induction of apoptosis (estimated from the sub-G1
content) occurred during the treatment period (Fig. 1B), in
agreement with previous results (24). In the absence of cispla-
tin, about 5% of the cells were in mitosis, as estimated by
fluorescence-activated cell sorter (FACS) analysis of serine 10
phosphorylation of histone H3; nocodazole-treated cells ar-
rested in G2 or M phase were used as a positive control (see
Fig. S1B in the supplemental material). The maximal reduction
FIG. 1. (A) mES cells were treated with 5 M cisplatin for different times (as indicated) followed by EdU labeling for 45 min. Flow cytometric
analysis evidenced a time-dependent inhibition of DNA synthesis. (B) mES cells were treated with 5 M cisplatin, and the sub-G1 cell content was
determined by flow cytometric analysis at different time points (as indicated). (C) The mitotic index of mES cells treated with 5 M cisplatin was
determined at different time points (as indicated) by flow cytometric analysis. (D) mES cells were treated with 5 M cisplatin and analyzed 0.5,
2, 4, and 8 h later with the indicated antibodies., untreated sample. Shown are the SILAC mass spectrometry spectra of -H2AX phosphopeptide
and unmodified H2A peptide. (E) Number of phosphopeptides (black bars) and unmodified peptides (gray bars) identified by MS analysis.
(F) Number of peptides containing 0, 1, 2, 3, and 4 phosphorylation sites. (G) Phosphorylation site distribution over serine, threonine, and tyrosine
residues.
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in mitotic index was observed after 4 h of cisplatin treatment
and persisted through 8 h (Fig. 1C). Cisplatin-mediated DNA
damage signaling manifested by -H2AX phosphorylation in-
creased with time, reaching its maximal level at 4 h posttreat-
ment, as evidenced by Western blotting and MS analysis (Fig.
1D). Together, these time course experiments indicated a com-
plete inhibition of DNA synthesis, a significant reduction of
mitotic index, and a strong induction of DNA damage signaling
after 4 h of cisplatin treatment.
Phosphoproteome analysis after cisplatin exposure. Stable
isotope labeling by amino acids in cell culture (SILAC) tech-
nology (43) was applied to quantitatively and qualitatively an-
alyze genomewide protein phosphorylation events following
exposure to cisplatin. mES cells were grown in medium con-
taining “lightly” (control cells) or “heavily” (treated cells) la-
beled forms of the amino acids arginine and lysine. Cells were
exposed to 5 M cisplatin for 4 h, mixed with untreated cells,
lysed, and subsequently digested with trypsin. The 4-h time
point was selected based on the kinetics of cisplatin-induced
stress responses (Fig. 1). Phosphopeptides were selectively en-
riched by means of a two-step phosphopeptide enrichment
procedure, i.e., SCX (strong cation exchange) chromatography
followed by TiO2 column separation and subjected to online
nanoflow liquid chromatography-tandem mass spectrometry
(nano-LC-MS/MS) analysis (27). A total of 14 fractions were
collected from SCX chromatography, and after TiO2 enrich-
ment, each fraction was analyzed by high-resolution tandem
mass spectrometry on an LTQ-Orbitrap Velos MS (41) using
higher-energy collisional dissociation (HCD) (40) for all
MS/MS events (Fig. 1E). The tandem mass spectra were iden-
tified by Mascot (www.matrixscience.com), and SILAC phos-
phopeptide pairs were quantified using the MaxQuant soft-
ware suite (8); the final data set showed 11,034 unique
phosphopeptides (false discovery rate [FDR] of 1%) origi-
nating from 3,395 proteins (see Table S1 in the supplemental
material). Most phosphopeptides contained only a single phos-
phorylation site (Fig. 1F), but multiple phosphorylation sites
were detected as well. Serine, threonine, and tyrosine phos-
phorylation sites comprised86.7%,13%, and0.3% of the
sites, respectively (Fig. 1G).
The quantified phosphorylation site data set revealed that
approximately 4% of the phosphopeptides underwent a more
than 2-fold change in phosphorylation level after exposure to
cisplatin, corresponding to 183 and 194 up- and downregulated
phosphopeptides, respectively. A total of 324 phosphorylation
sites were 1.5- to 2-fold upregulated, while 725 phosphoryla-
tion sites were found to be 1.5- to 2-fold downregulated (Fig.
2A; see Table S1 in the supplemental material). Many of the
top 50 upregulated phosphopeptides stemmed from proteins
that are known to play key roles in DNA repair, chromatin
remodeling, cell cycle checkpoints (G1/S and G2/M), and tran-
scription (Fig. 2B). Typically, multiple individual phosphoryla-
tion sites were identified for each protein, but interestingly, 44
proteins (most of them related to DNA repair) were found to
contain both upregulated phosphorylation sites and downregu-
lated (dephosphorylated) sites (see Fig. S2 in the supplemental
material).
To examine the general validity of our findings, we per-
formed an independent experiment with the same ES cell line
employing an identical concentration of cisplatin and exposure
time (4 h), as well as identical protocols to purify phosphopep-
tides (see Fig. S6A in the supplemental material). The final
data set showed 11,966 unique phosphopeptides (see Table S6
in the supplemental material). The quantified phosphorylation
site data set revealed that 224 and 706 up- and downregulated
phosphopeptides, respectively, underwent more than 2-fold
change in phosphorylation level after exposure to cisplatin (see
Fig. S6C).
Cellular network analysis. Network and pathway analysis
using MetaCore software indicated that processes related to
DDR (i.e., cell cycle control, checkpoint activation, and apop-
tosis) were significantly overrepresented among proteins con-
taining upregulated phosphorylation sites (1.5-fold and 2-
fold) (Fig. 2C to E; see Fig. S3 in the supplemental material).
The central signal transducers in the early cellular response to
cisplatin are the protein kinases ATM and ATR (Fig. 3A and
B). On the other hand, the analysis of proteins containing
downregulated phosphorylation sites identified cytoskeleton
and mitotic processes (1.5-fold and 2-fold). Anaphase-pro-
moting complex (APC), cell adhesion, Rho GTPases (RAC1
and Cdc42), and mitosis initiation pathways were found to be
significantly affected (Fig. 2D to F; see Fig. S3 in the supple-
mental material). Together, the strong inhibition of replicative
DNA synthesis, the formation of DNA strand breaks, and the
reduction of the mitotic index fit well with the activation of
DDR (i.e., cell cycle checkpoints, DNA repair, and apoptosis)
and inactivation of processes related to mitosis. Analysis of
phosphorylation levels revealed the same processes signifi-
cantly affected by cisplatin, when thresholds were set at 1.5- or
2.0-fold changes. This finding indicates that a 1.5-fold change
in the phosphoprotein level is a relevant threshold to identify
proteins and processes related to the genotoxic stress induced
by cisplatin.
Activation of ATM and ATR in response to cisplatin. In line
with recent investigations (2, 3, 30, 59), we found that DNA-
damaging agents such as cisplatin provoke activation of ATM
and ATR kinases as the substrate consensus sequence (SQ-TQ
motif) of these kinases was significantly overrepresented (84
out of 183 peptide count) among the 2-fold-upregulated
phosphorylation sites (Fig. 3A). Interestingly, whereas the
phosphorylation of S1987, the important SQ motif in murine
ATM required for its activation (45), was found to be upregu-
lated, phosphorylation of SQ motifs in ATR was not detected.
Notably, phosphorylation at S440 in ATR was found to be
upregulated, suggesting that the activity of this kinase may also
be modulated by phosphorylation at a site different from the
SQ motif. Direct targets of ATR and ATM included proteins
involved in the initial enzymatic processing step of DNA dam-
age, such as DNA strand breaks (i.e., Nbs1, Rad50, and
H2AX), signaling mediators (i.e., MDC1 and 53BP1), repair
factors (i.e., BRCA1, BARD1, and FANCD2), and checkpoint
activators (i.e., CHK1) (1). Interestingly, we identified multiple
regulated phosphorylation sites on chromatin remodeling pro-
teins (i.e., SMARCAD1, Chd1, Ino80, Rsf1, and HMGA1), E3
ubiquitin ligases (i.e., Np95, Ube3a, Huwe1, Rnf2, UBR7,
Mdm2, TRIM33, and RNF19A), and a SUMO protein ligase
(i.e., RanBP2). Moreover, proteins known to bind cisplatin-
DNA adducts such as the high-mobility group proteins
HMGA1 and HMGA2 (62), revealed altered phosphorylation
site abundance after treatment. The phosphorylation of the
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FIG. 2. (A) Phosphopeptide ratio plot. Red dots indicate phosphopeptides that were found to be2-fold up- or downregulated after cisplatin treatment;
green dots indicate phosphopeptides that showed 1.5- to 2-fold up- and downregulation after cisplatin treatment; blue dots indicate phosphopeptides that were
not affected by cisplatin treatment. The y axis represents signal intensity of the ions, and it is related to the power (amplitude squared) of the signal sine wave.
(B) Top 50 upregulated phosphopeptides. (C) Top 50 downregulated phosphopeptides. (D) MetaCore network analysis of proteins containing 1.5-fold-
upregulated phosphorylation sites after cisplatin treatment. (E) MetaCore network analysis of proteins containing more than 1.5-fold-downregulated phosphor-
ylation sites after cisplatin treatment. (F) MetaCore network analysis of proteins containing2-fold-upregulated phosphorylation sites after cisplatin treatment.
(G) MetaCore network analysis of proteins containing 2-fold downregulated phosphorylation sites after cisplatin treatment.
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acidic C-terminal tail of HMGA2 has been associated with
reduced DNA binding activity (56). Phosphorylation sites S100,
S101, and S104 on the acidic C-terminal tail and S44 outside that
domain of HMGA2 were found to be downregulated after
cisplatin treatment, suggesting increased DNA binding to cis-
platin-modified DNA. In contrast, we observed enhanced
phosphorylation of the S102 and S103 sites on the acidic C-ter-
minal tail of HMGA1 after cisplatin treatment, and, moreover,
the phospho-S9 (SQ motif) was present in the top 10 cisplatin-
upregulated phosphorylation sites.
Kinase domain loop phosphorylation site changes by cispla-
tin stress response. Based on the consensus sequence, about
half of the2-fold-upregulated phosphorylation sites were not
canonical substrates of ATM or ATR, revealing substantial
involvement of other kinases in the genotoxic stress response.
The activity of many kinases is modulated by phosphorylation
of the kinase domain loop located between the conserved
amino acid sequence motifs DFG and APE (35). This domain
plays a crucial role in substrate recognition. Phosphorylation of
residues in this segment is frequently required for the correct
alignment between the substrate and the catalytic site of the
kinases (20), and the phosphorylation status of the activation
loop can therefore be used as a proxy for kinase activity.
Eleven kinases mainly belonging to the MAPK family were
identified to be phosphorylated in the activation loop after
cisplatin treatment (Fig. 4A). Plk1, a kinase that plays essential
roles in the regulation of mitosis by coordinating spindle as-
sembly and dynamics, was found to be specifically dephosphor-
ylated in its activation loops after cisplatin treatment. We
tested the biological relevance of 11 of the regulated kinases
for cisplatin-induced toxicity by siRNA-mediated knockdown
and demonstrated a novel protective role for 3 of them (CDK7,
Plk1, and KPCD1) (Fig. 4B). In order to test the off-target
effects, four individual siRNAs were used to knock down
CDK7, Plk1, and KPCD1, respectively, and the extent of
knockdown was tested by Western blotting (see Fig. S4 in the
supplemental material). We note here that a significant reduc-
tion in cell survival was detected for the Plk1 knockdown in the
absence of cisplatin treatment, indicating a critical role of this
kinase in normal cell growth (see Fig. S4) (65).
Effects on mitosis. Analysis of kinase motifs among the
phosphorylation sites showed a significant enrichment of CDK,
ERK, and Aurora kinase substrates among the downregulated
phosphorylation sites (Fig. 3B). In response to persistent geno-
toxic stress, ATM and ATR and the subsequent Chk1/Chk2
signaling cascade prevent activation of Cdk1/cyclin B, thereby
blocking entry into mitosis (1). The depletion of mitotic cells
evidenced by FACS analysis (Fig. 1C) is consistent with the
activity of these cell cycle kinases, as indicated by the phos-
phoproteomic data set. Following DNA damage, two mitosis-
specific kinases, Cdk1 and Plk1, are inactivated by inhibitory
phosphorylation (T14 and Y15) (36) and dephosphorylation
(T210) (64) events, respectively. T14 and Y15 phosphorylation
of Cdk1 and the dephosphorylation of the activation loop T210
of Plk1 were evident in our data (see Table S1 in the supple-
mental material). Several Plk1 targets involved in mitosis have
been identified (34), including FoxM1; this protein was found
to be dephosphorylated after cisplatin treatment (see Table
S1). The FoxM1 protein is an important transcription factor
involved in the regulation of mitotic entry (25, 71), and phos-
phorylation of FoxM1 by Plk1 and Cdk1 regulates the tran-
scription network essential for mitotic progression (14). Re-
markably, a wide range of proteins related to mitotic events
were found to be dephosphorylated: i.e., KNSL1, nucleolin,
histone H1, and the anaphase-promoting complex (APC).
APC is a multisubunit protein complex with E3 ubiquitin ligase
acitivity essential for proteolysis, a key mechanism that drives
the events of mitosis. APC1, APC2, Cdc20, Cdh1, and Cdc23
subunits of the anaphase-promoting complex were found to be
FIG. 3. (A) Consensus sequence for ATM, ATR, and DNA-PK substrates among the 2-fold-upregulated phosphorylation sites. (B) Con-
sensus sequence for different kinases among upregulated, downregulated, and unmodified phosphorylation sites.
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down-phosphorylated, and very likely this alteration may facil-
itate the binding of Emi1, an inhibitor of APC (63).
Effects on cytoskeleton. Cellular movement is orchestrated
by microtubules and actin cytoskeleton and is controlled by the
activity of Rho GTPases (73). Prominent Rho GTPase family
members are Rac1 and Cdc42, which induce the formation of
extensions (lamellipodia) and stimulate actin polymerization at
the leading edge of the cell together with the formation of new
adhesion sites to the matrix (51). Cytoskeleton processes and,
in particular, Rac-1 (P  10e5) and Cdc42 (P  10e4)
pathways were found to be affected by genotoxic stress (see
Fig. S3 in the supplemental material). Proteins associated with
the RAC-1 and Cdc42 pathways (i.e., ABR, ECT2, DBL,
RacGAP1, p200RhoGAP, ARCGAP22, and ARHGAP12) were
found to be dephosphorylated on proline-directed serine/thre-
onine sites (potential CDK or MAPK substrates) or sites that
are targeted by casein kinases (in an acidic amino acid con-
text). To study the effect of cisplatin on cytoskeleton structure,
we monitored the actin organization in mES cells after treat-
ment (Fig. 4C). Cytoskeleton remodeling and specific micro-
FIG. 4. (A) Analysis of the kinase domain loop located between the conserved sequence from DFG to APE. (B) The cellular sensitivity
for cisplatin after siRNA knockdown was determined by an ATP monitoring system. Knockdown of CDK7, PLK1, or KPCD1 kinases
significantly reduced cell survival after cisplatin treatment (Student’s t test). siGFP (control 1) and siLAMIN C/A (control 2) were used as
negative controls (two independent experiments). (C) Effects of cisplatin on cytoskeleton structure. mES cells were exposed for 4 and 8 h
to cisplatin (5 M) treatment and stained with DY554-phalloidin and DAPI (4	,6-diamidino-2-phenylindole) (nuclei). The arrows indicate
microspikes.
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spike formation were clearly visible in cells treated with cispla-
tin, confirming the results of the pathway analysis obtained
from the phosphoproteome.
Proteome and transcriptome. Nonphosphorylated peptides
were analyzed to rule out that changes in overall protein levels
might be responsible for the observed changes in phosphory-
lation site levels. Quantitative profiles were obtained for 4,349
proteins (Fig. 5A) out of a total of 5,917 proteins (see Table S2
in the supplemental material), based on the quantification of
16,305 nonphosphorylated unique peptides (see Table S3 in
the supplemental material). The abundance of most proteins
that contained up- or downregulated phosphorylation sites did
not change significantly during cisplatin treatment, indicating
that the majority of observed phosphorylation changes were
not due to alterations in protein quantity (Fig. 5C to E). In-
terestingly, cellular levels of 455 proteins were found to be
altered when proteomic data analysis was performed with a
statistical rigor of P  0.05. Network analysis identified cyto-
skeleton remodeling as one of the most prominent affected
pathways. In particular, the NOTCH signaling pathway was
statistically found to be significantly affected (see Fig. S3 in the
supplemental material). MetaCore analysis shows an enrich-
ment of p53 target genes (i.e., 49 out of 455 proteins) double
the expected frequency (P  10e6), suggesting a p53-depen-
dent response, in line with previous studies (24). We examined
how the proteome correlates to the mES transcriptome previ-
ously generated under identical conditions of cell growth and
cisplatin exposure (24). Of a total of 3,616 Entrez gene iden-
tifications (IDs) shared among the gene expression and protein
data sets, 386 proteins and 56 mRNAs transcripts were found
to be significantly affected by cisplatin treatment (P  0.05),
with surprisingly only 5 gene IDs being in common (see Table
S5 in the supplemental material). A selected group of genes
was examined by RT-PCR and Western blot analysis to quan-
tify gene expression and protein levels in mES cells after cis-
platin treatment. Indeed, significant changes in protein levels
were found for Cdh1, p53, Centrin2, and Mark2 by immuno-
blotting, whereas the corresponding mRNA transcripts were
not affected after cisplatin treatment (see Fig. S5 in the sup-
plemental material). Together, these data indicate that alter-
ations in protein and transcript quantities do not correlate well
at the individual gene level after cisplatin treatment. In con-
trast, pathway analysis based on transcriptomic, proteomic,
and phosphoproteomic data revealed a large overlap in the
affected processes (Fig. 6). The cell cycle was the most prom-
inent pathway affected at the transcriptome and phosphopro-
teome level, whereas DNA repair pathways were only signifi-
cantly affected at the phosphoproteome level. In contrast,
changes at the overall protein level primarily involved pro-
cesses associated with cytoskeleton regulation.
DISCUSSION
Cisplatin is a widely used anticancer drug, and, therefore,
understanding of the molecular changes that underlie the bi-
ological consequences of treatment with this drug is of critical
importance. Protein phosphorylation is one of the most prom-
inent posttranslational modifications that are triggered by cis-
platin treatment, and, therefore, global phosphoproteome
analysis is an excellently suited approach to identify molecular
components and cellular pathways affected by cisplatin.
Inhibition of transcription and replication by cisplatin-in-
duced DNA lesions, and subsequently the generation of DNA
strand breaks, activates the ATR and ATM kinases as well as
p38 MAPK/MK2 pathway (1, 49, 50). Consistently, we found
upregulation of S1987 phosphorylation in ATM that is required
for its activation (45). Upregulation of ATR phosphorylation
was observed at S440, a site that lacks the SQ motif and likely
represents the site targeted by the NEK6 kinase. This kinase
belongs to a large family of Ser/Thr kinases that have critical
roles in coordinating microtubule dynamics during mitotic pro-
gression (46). This phosphorylation site has not been previ-
ously mapped and might represent a novel site involved in
ATR activation. The top 50 upregulated phosphorylation sites
include a significant number of direct ATR and ATM targets
related to DDR—most notably proteins involved in the pro-
cessing step of double-strand breaks (DSB), DNA damage
signaling, stalled replication/transcription forks, checkpoint ac-
tivation, and chromatin remodeling proteins. In addition, E3
ubiquitin and SUMO-protein ligases were observed to be reg-
ulated by phosphorylation events highlighting the cross talk
between phosphorylation and other posttranslational modifi-
cations in response to genotoxic stress (2). In contrast to the
large-scale proteomic analysis of SQ-specific phosphorylation
sites in response to DNA damage induced by ionizing radiation
(IR) and UV (30, 59), our global phosphoproteomic strategy
allowed identification of putative ATM/ATR-dependent and
-independent phosphorylation events. Indeed, DNA repair
proteins such as BRCA1, Rad50, p53BP1, FANCI, and
BARD-1 were found to contain upregulated phosphorylation
sites unrelated to ATM and ATR activity. As these data are
not based on direct experimental evidence, we cannot exclude
that ATM/ATR may also phosphorylate at nonconsensus sites.
Moreover, 44 proteins (mostly involved in DNA repair and
including BRCA1 and Ino80; see Fig. S2 in the supplemental
material) underwent differential phosphorylation of adjacent
sites (2 to 5 amino acids). Differential phosphorylation might
serve to create a molecular switching mechanism (2) by a
tightly controlled activity of several kinases and phosphatases.
Different types of posttranslational modifications controlled by
such a mechanism might dynamically regulate the DDR—for
example, the assembly and disassembly of factors at sites of
damage (1).
Several of the HMG domain proteins recognize cisplatin
adducts and display a selective affinity for clinically effective
platinum drugs (22). HMGA proteins are expressed at a
high levels during embryonic development, whereas they are
barely detectable in differentiated or nonproliferating cells;
it is noteworthy that these proteins are highly reexpressed
following neoplastic transformation (57). HMGA1 and
HMGA2 were found to be differentially phospho-regulated
after cisplatin treatment. To our knowledge, these are the
first in vivo data showing a discrepancy in phosphorylation
states between HMGA1 and HMGA2 in response to geno-
toxic stress. The finding of differential phosphorylation pro-
files within the HMGA family after cisplatin treatment
might offer potential targets for improved cisplatin cancer
therapy, considering that these proteins are overexpressed
in cancers of different origins.
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FIG. 5. (A) Unmodified peptide ratio plot. Red dots, significantly (P  0.001) regulated peptides after cisplatin treatment; green dots,
significantly (P  0.05) regulated peptides after cisplatin treatment; blue dots, unmodified peptides after cisplatin treatment. The y axis represents
signal intensity of the ions and is related to the power (amplitude squared) of the signal sine wave. (B) MetaCore network analysis of significantly
affected proteins (P  0.05) after cisplatin addition. (C) Abundance distributions of all proteins and proteins containing upregulated phosphor-
ylation sites (1.5-fold) (D) Abundance distributions of all proteins and proteins containing downregulated phosphorylation sites (1.5-fold).
(E) Abundance distributions of all proteins and proteins containing unmodified phosphorylation sites.
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The outcome of an independent replicate experiment with
the same ES cells demonstrated the high reproducibility of the
cisplatin-induced protein phosphorylation. The results also
showed that ATM and ATR consensus sequences were signif-
icantly overrepresented among hyperphosphorylated peptides
(see Fig. S6D in the supplemental material). The phosphopep-
tide ratio correlation between the two replicates is 0.61 (Pear-
son correlation coefficient, R; see Fig. S6A) based on 7,275
FIG. 6. Comparison of significantly affected pathways (MetaCore network analysis) by cisplatin at the transcriptomic (mRNA transcripts; P 
0.05), proteomic (proteins; P  0.05) and phosphoproteomic (phosphoprotein; P  0.05) levels.
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unique phosphopeptides identified in both experiments (see
Table S7 in the supplemental material). These results are close
to those achieved in a recent study using a similar experimental
approach (52). A much higher correlation (R  0.88) was
found when the analysis was limited to putative ATM/ATR
substrate peptide ratios (see Fig. S6A, B, and E). Importantly,
network analysis identified DDR and cytoskeleton regulation
as affected cisplatin processes in both experiments. Together
these results demonstrate the reproducibility and general va-
lidity of our findings (see Fig. S6F and G).
Our results indicate that the cellular response to genotoxic
stress involves a large variety of protein kinases and phospha-
tases. Indeed, 11 kinases were identified to be regulated at
phosphorylation sites in the activation loop after cisplatin
treatment (Fig. 4A). Most of those regulated belong to the
MAPK family, but a kinase not related to the MAPK family
(i.e., Plk1 essential in the regulation of mitosis) was found to be
dephosphorylated as well. Mitogen-activated protein kinases
(MAPKs) are critical components of the signaling network
activated by genotoxic stress and are critical in deciding cell
fate in response to cisplatin (5). Particularly, in the absence of
p53, cells depend on p38 MAPK/MK2 for cell cycle arrest and
survival after cisplatin (49). Here we show that the kinase
domain of MK14 (p38) is activated by specific phosphoryla-
tion of the activation loop TXY motif after cisplatin addition.
Knockdown of CDK7 significantly increased cell toxicity af-
ter cisplatin treatment. The cyclin-dependent protein kinase
CDK7 forms a trimeric complex with cyclin H and MAT1 and
is both a Cdk-activating kinase (CAK) (10, 48) and an essential
component of the transcription factor TFIIH, involved in tran-
scription initiation and nucleotide excision repair (55). In ad-
dition, knockdown of Plk1 and KPCD1 also increased cispla-
tin-mediated cytotoxicity (Fig. 4B). KPCD1 is a member of the
protein kinase C (PKC) family involved in extracellular recep-
tor-mediated signal transduction pathways (19). The mitosis-
specific kinase Plk1 has been shown to play an essential role in
the regulation of mitotic progression, including mitotic entry,
spindle formation, chromosome segregation, and cytokinesis;
moreover, it has been found to be overexpressed in different
types of tumors (60). Inhibition of Plk1 is an efficient way to
establish an irreversible G2 arrest after DNA damage induc-
tion in specific cancers with nonfunctional p53. In these cells,
typical G1 arrest is lost in response to DNA damage and cells
display a stronger dependence on the G2 DNA damage check-
point for protection against genotoxic insults (67) Our data
suggest that the cellular response to inactivate PKL1 is di-
rected toward prevention of mitotic entry in favor of an apop-
tosis process (28), which is in accordance with transcriptomic
and phosphoproteomic analyses. Currently, several Plk inhib-
itors are in phase I or II clinical studies (9, 18, 33), and in
cancers with nonfunctional p53, Plk1 inhibition serves as a
potent adjuvant therapy when combined with a DNA-damag-
ing regimen such as cisplatin (65). Together, our results clearly
indicate that dissection of the cellular responses induced by
cisplatin using phosphoproteome analysis in concert with func-
tional genomics allows unraveling of targets and pathways that
enhance the cytotoxic effects of cisplatin.
Proteins that were identified to be differentially phosphory-
lated upon cisplatin treatment also belonged to biological pro-
cesses and structures not classified as or related to core DDR
processes. In fact, unanticipated processes associated with cy-
toskeleton events were identified by network analysis of pro-
teins containing downregulated phosphorylation sites, and in
particular, Rac-1 and Cdc42 pathways were found to be af-
fected by cisplatin. The actin component of the cytoskeleton is
dynamically implicated in a variety of cell functions, including
regulation of cell shape, adhesion, and motility, and recent
studies underline mechanisms of cisplatin-mediated inhibition
on invasion and migration of human cancer cells (21, 44, 47).
Cytoskeleton remodeling and specifically the induction of mi-
crospike formation were clear effects of cisplatin treatment
(Fig. 4C). These results are in line with reports on microspike
formation related to Cdc42 (66). The regulation of the phos-
pho state of Rho GTPases (members of the Rac-1 and Cdc42
pathways) shown in this study is consistent with the observed
cisplatin-mediated changes in cell morphology. Moreover, the
link between cisplatin and Rac-1/Cdc42 pathways is relevant in
view of the fact that Cdc42 activity is associated with genome
maintenance, cellular senescence regulation, and aging (72).
Although classically regarded as a nuclear DNA-damaging
agent, recent studies support a more promiscuous mode of
action for cisplatin (12, 29, 54, 75). The current phosphopro-
teome analysis of kinase targets and their predicted activated
substrates supports this finding by confirming previous data
and providing evidence for the extranuclear targeting function
that might play a role in cisplatin-induced toxicity and in cell
motility. A better understanding of the mechanisms of cisplatin
action may provide novel therapeutic strategies that would
block metastatic progression and reducing dissemination of
tumor cells.
We tested the hypothesis whether changes in transcription
profiling after cisplatin correlate with changes observed at the
protein level. Consistent with previously published data (42),
we found no clear correlation between changes in the relative
levels of transcripts and corresponding proteins. This lack of
correlation might be due to the fact that the cellular mecha-
nisms involved in regulation of stability/degradation differ be-
tween mRNAs and their encoded proteins. This finding
indicates that the pieces of information derived from transcrip-
tomic and proteomic analyses are different, but when merged
generate a more comprehensive view of the signaling pathways
affected by stressors. Interestingly, the phosphoproteomic
analysis performed in our study led to the identification of
most of the pathways that were affected at the transcriptome or
proteome level. However, the impact of cisplatin on the DNA
damage repair pathways was only manifested in the phospho-
proteome analysis, indicating that phosphorylation events are
key to activate DNA repair pathways after genotoxic stress
induced by cisplatin or in general to genotoxic agents that
induce replication and transcription blocking lesions.
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